MRI Assisted Focal Boost With HDR Monotherapy for Prostate Cancer Patients

NAActive, not recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 24, 2015

Primary Completion Date

May 30, 2017

Study Completion Date

May 13, 2027

Conditions
Prostate Cancer
Interventions
RADIATION

MRI assisted focal boost with HDR monotherapy

Prior to brachytherapy treatment, a multiparametric MRI will be obtained for identification of the dominant intraprostatic lesion (DIL) and fused with the preplanning transrectal ultrasound. A total of 19 Gy will be prescribed to the prostate, organ at risk limits will be observed and up to 22.5 Gy can be delivered to the DIL

Trial Locations (1)

M4N 3M5

Sunnybrook Health Sciences Centre, Toronto

All Listed Sponsors
lead

Sunnybrook Health Sciences Centre

OTHER

NCT02623933 - MRI Assisted Focal Boost With HDR Monotherapy for Prostate Cancer Patients | Biotech Hunter | Biotech Hunter